Advertisement

Japanese Journal of Ophthalmology

, Volume 55, Issue 5, pp 435–443 | Cite as

VEGF gene polymorphism and response to intravitreal bevacizumab and triple therapy in age-related macular degeneration

  • Isao Nakata
  • Kenji YamashiroEmail author
  • Hideo Nakanishi
  • Akitaka Tsujikawa
  • Atsushi Otani
  • Nagahisa Yoshimura
Clinical Investigation

Abstract

Purpose

To investigate the association between the vascular endothelial growth factor (VEGF) gene and response to either intravitreal bevacizumab (IVB) or photodynamic therapy with intravitreal triamcinolone acetonide and IVB (triple therapy) for neovascular age-related macular degeneration (AMD).

Methods

The study consisted of 94 patients with neovascular AMD who underwent IVB and 79 patients with neovascular AMD who underwent triple therapy. Genotypes were determined for four selected tagging single-nucleotide polymorphism (SNP)s of the VEGF gene.

Results

Of the four SNPs studied, one SNP (rs699946) was associated significantly with visual acuity (VA) changes 12 months after treatment—irrespective of whether they received IVB alone (P = 0.044) or triple therapy 0.010). Baseline VA was not significantly different among the three genotypes of rs699946 in either treatment group. There were no significant differences in the number of treatments, incidence of recurrence, or the period until the recurrence according to VEGF rs699946 genetic variant.

Conclusions

The VEGF gene SNP rs699946 was associated with response to IVB alone and to triple therapy in this study. The G allele in SNP rs699946 can thus be applied as a marker for better visual prognosis in patients with neovascular AMD who receive either IVB or triple therapy.

Keywords

Bevacizumab Photodynamic therapy Vascular endothelial growth factor 

Notes

Acknowledgments

The authors wish to thank Drs Norimoto Gotoh, Hisako Hayashi, Sotaro Ooto, and Hiroshi Tamura for their valuable contributions to this study. This study was supported in part by Grants-in-aid for scientific research (nos. 21249084 and 200791294) from the Japan Society for the Promotion of Science, Tokyo, Japan, and the Japan National Society for the Prevention of Blindness, Tokyo, Japan.

References

  1. 1.
    Brown MM, Brown GC, Sharma S, Stein JD, Roth Z, Campanella J, et al. The burden of age-related macular degeneration: a value-based analysis. Curr Opin Ophthalmol. 2006;17:257–66.PubMedGoogle Scholar
  2. 2.
    Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol. 1999;117:1329–45.Google Scholar
  3. 3.
    Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805–16.CrossRefPubMedGoogle Scholar
  4. 4.
    Chakravarthy U, Adamis AP, Cunningham ET, Jr, Goldbaum M, Guyer DR, Katz B, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology. 2006;113:1508 e1–25.PubMedGoogle Scholar
  5. 5.
    Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112:1035–47.CrossRefPubMedGoogle Scholar
  6. 6.
    Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31.CrossRefPubMedGoogle Scholar
  7. 7.
    Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363–72 e5.CrossRefPubMedGoogle Scholar
  8. 8.
    Heier JS, Antoszyk AN, Pavan PR, Leff SR, Rosenfeld PJ, Ciulla TA et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology. 2006;113:633 e1–4.CrossRefPubMedGoogle Scholar
  9. 9.
    Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1996;37:855–68.PubMedGoogle Scholar
  10. 10.
    Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996;37:1929–34.PubMedGoogle Scholar
  11. 11.
    Frank RN, Amin RH, Eliott D, Puklin JE, Abrams GW. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol. 1996;122:393–403.CrossRefPubMedGoogle Scholar
  12. 12.
    Yip PP, Woo CF, Tang HH, Ho CK. Triple therapy for neovascular age-related macular degeneration using single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone. Br J Ophthalmol. 2009;93:754–8.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Ahmadieh H, Taei R, Soheilian M, Riazi-Esfahani M, Karkhaneh R, Lashay A, et al. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration. BMC Ophthalmol. 2007;7:10.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Tammela T, Enholm B, Alitalo K, Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc Res. 2005;65:550–63.CrossRefPubMedGoogle Scholar
  15. 15.
    Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger EA. Common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res. 2000;37:443–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K, et al. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes. 2002;51:1635–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine. 2000;12:1232–5.CrossRefPubMedGoogle Scholar
  18. 18.
    Petrovic MG, Korosec P, Kosnik M, Osredkar J, Hawlina M, Peterlin B, et al. Local and genetic determinants of vascular endothelial growth factor expression in advanced proliferative diabetic retinopathy. Mol Vis. 2008;14:1382–7.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, et al. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer. 2003;106:468–71.CrossRefPubMedGoogle Scholar
  20. 20.
    Diao LP, Yu XM, Gao YH, Li Y, Liu HS, Liu LH, et al. Association of VEGF genetic polymorphisms with the clinical characteristics of non-Hodgkin′s lymphoma. J Cancer Res Clin Oncol. 2009;135:1473–81.CrossRefPubMedGoogle Scholar
  21. 21.
    Zarbock R, Hendig D, Szliska C, Kleesiek K, Gotting C. Vascular endothelial growth factor gene polymorphisms as prognostic markers for ocular manifestations in pseudoxanthoma elasticum. Hum Mol Genet. 2009;18:3344–51.CrossRefPubMedGoogle Scholar
  22. 22.
    Girnita DM, Brooks MM, Webber SA, Burckart GJ, Ferrell R, Zdanowicz G, et al. Genetic polymorphisms impact the risk of acute rejection in pediatric heart transplantation: a multi-institutional study. Transplantation. 2008;85:1632–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Kim JG, Chae YS, Sohn SK, Cho YY, Moon JH, Park JY, et al. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer. Clin Cancer Res. 2008;14:62–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Kim DH, Lee NY, Lee MH, Sohn SK, Do YR, Park JY. Vascular endothelial growth factor (VEGF) gene (VEGFA) polymorphism can predict the prognosis in acute myeloid leukaemia patients. Br J Haematol. 2008;140:71–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Immonen I, Seitsonen S, Tommila P, Kangas-Kontio T, Kakko S, Savolainen ER et al. Vascular endothelial growth factor gene variation and the response to photodynamic therapy in age-related macular degeneration. Ophthalmology. 2009.Google Scholar
  26. 26.
    Thorisson GA, Smith AV, Krishnan L, Stein LD. The International HapMap Project Web site. Genome Res. 2005;15:1592–3.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Bewick V, Cheek L, Ball J. Statistics review 10: further nonparametric methods. Crit Care. 2004;8:196–9.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Goverdhan SV, Hannan S, Newsom RB, Luff AJ, Griffiths H, Lotery AJ. An analysis of the CFH Y402H genotype in AMD patients and controls from the UK, and response to PDT treatment. Eye. 2008;22:849–54.CrossRefPubMedGoogle Scholar
  29. 29.
    Brantley MA Jr, Fang AM, King JM, Tewari A, Kymes SM, Shiels A. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology. 2007;114:2168–73.CrossRefPubMedGoogle Scholar
  30. 30.
    Brantley MA Jr, Edelstein SL, King JM, Plotzke MR, Apte RS, Kymes SM, et al. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to photodynamic therapy. Eye. 2009;23:626–31.CrossRefPubMedGoogle Scholar
  31. 31.
    Lee KY, Vithana EN, Mathur R, Yong VH, Yeo IY, Thalamuthu A, et al. Association analysis of CFH, C2, BF, and HTRA1 gene polymorphisms in Chinese patients with polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci. 2008;49:2613–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Gotoh N, Yamada R, Hiratani H, Renault V, Kuroiwa S, Monet M, et al. No association between complement factor H gene polymorphism and exudative age-related macular degeneration in Japanese. Hum Genet. 2006;120:139–43.CrossRefPubMedGoogle Scholar
  33. 33.
    Fuse N, Miyazawa A, Mengkegale M, Yoshida M, Wakusawa R, Abe T, et al. Polymorphisms in complement factor H and hemicentin-1 genes in a Japanese population with dry-type age-related macular degeneration. Am J Ophthalmol. 2006;142:1074–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Uka J, Tamura H, Kobayashi T, Yamane K, Kawakami H, Minamoto A, et al. No association of complement factor H gene polymorphism and age-related macular degeneration in the Japanese population. Retina. 2006;26:985–7.CrossRefPubMedGoogle Scholar
  35. 35.
    Okamoto H, Umeda S, Obazawa M, Minami M, Noda T, Mizota A, et al. Complement factor H polymorphisms in Japanese population with age-related macular degeneration. Mol Vis. 2006;12:156–8.PubMedGoogle Scholar
  36. 36.
    Mori K, Gehlbach PL, Kabasawa S, Kawasaki I, Oosaki M, Iizuka H, et al. Coding and noncoding variants in the CFH gene and cigarette smoking influence the risk of age-related macular degeneration in a Japanese population. Invest Ophthalmol Vis Sci. 2007;48:5315–9.CrossRefPubMedGoogle Scholar
  37. 37.
    Richardson AJ, Islam FM, Guymer RH, Cain M, Baird PN A. Tag-single nucleotide polymorphisms approach to the vascular endothelial growth factor-A gene in age-related macular degeneration. Mol Vis. 2007;13:2148–52.PubMedGoogle Scholar
  38. 38.
    Boekhoorn SS, Isaacs A, Uitterlinden AG, van Duijn CM, Hofman A, de Jong PT, et al. Polymorphisms in the vascular endothelial growth factor gene and risk of age-related macular degeneration: the Rotterdam Study. Ophthalmology. 2008;115:1899–903.CrossRefPubMedGoogle Scholar
  39. 39.
    Abhary S, Burdon KP, Gupta A, Lake S, Selva D, Petrovsky N, et al. Common sequence variation in the VEGFA gene predicts risk of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2009;50:5552–8.CrossRefPubMedGoogle Scholar
  40. 40.
    Kim DH, Xu W, Kamel-Reid S, Liu X, Jung CW, Kim S et al. Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy. Ann Oncol. 2009.Google Scholar
  41. 41.
    Del Bo R, Ghezzi S, Scarpini E, Bresolin N, Comi GP. VEGF genetic variability is associated with increased risk of developing Alzheimer′s disease. J Neurol Sci. 2009;283:66–8.CrossRefPubMedGoogle Scholar
  42. 42.
    Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–44.CrossRefPubMedGoogle Scholar
  43. 43.
    Kong SY, Park JW, Lee JA, Park JE, Park KW, Hong EK, et al. Association between vascular endothelial growth factor gene polymorphisms and survival in hepatocellular carcinoma patients. Hepatology. 2007;46:446–55.CrossRefPubMedGoogle Scholar
  44. 44.
    Perrin RM, Konopatskaya O, Qiu Y, Harper S, Bates DO, Churchill AJ. Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia. 2005;48:2422–7.CrossRefPubMedGoogle Scholar
  45. 45.
    Pabst S, Karpushova A, Diaz-Lacava A, Herms S, Walier M, Zimmer S et al. VEGF gene haplotypes are associated with sarcoidosis. Chest. 2009.Google Scholar
  46. 46.
    Ishida S, Usui T, Yamashiro K, Kaji Y, Amano S, Ogura Y, et al. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med. 2003;198:483–9.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Sacu S, Michels S, Prager F, Weigert G, Dunavoelgyi R, Geitzenauer W, et al. Randomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: long-term results. Eye (Lond). 2009;23:2223–7.CrossRefGoogle Scholar

Copyright information

© Japanese Ophthalmological Society 2011

Authors and Affiliations

  • Isao Nakata
    • 1
    • 2
  • Kenji Yamashiro
    • 1
    Email author
  • Hideo Nakanishi
    • 1
    • 2
  • Akitaka Tsujikawa
    • 1
  • Atsushi Otani
    • 1
  • Nagahisa Yoshimura
    • 1
  1. 1.Department of Ophthalmology and Visual SciencesKyoto University Graduate School of MedicineKyotoJapan
  2. 2.Center for Genomic Medicine, Kyoto University Graduate School of MedicineKyotoJapan

Personalised recommendations